Indication
Myocardial ischemia
Myocardial ischemia is a cardiovascular condition defined by a critical imbalance between coronary blood flow and myocardial metabolic demand, leading to inadequate perfusion and oxygenation of the heart muscle. Read more about Myocardial ischemia
0 drugs 0 manufacturers
Drugs that treat it
Common Myocardial ischemia therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMyocardial ischemia is a cardiovascular condition defined by a critical imbalance between coronary blood flow and myocardial metabolic demand, leading to inadequate perfusion and oxygenation of the heart muscle.
It predominantly affects adults with obstructive atherosclerotic coronary artery disease, microvascular dysfunction, or coronary vasospasm.
Pathophysiologically, cellular hypoxia triggers a shift to anaerobic glycolysis, impaired contractile function, and tissue acidosis, which can progress to cardiomyocyte necrosis if perfusion is not promptly restored.
Clinically, it manifests along a continuum ranging from silent ischemia to exertional angina pectoris, dyspnea, and acute coronary syndromes with ischemic electrocardiographic abnormalities.
- nih.gov
Myocardial ischemia is a cardiovascular condition defined by a critical imbalance between coronary blood flow and myocardial metabolic demand, leading to inadequate perfusion and oxygenation of the heart muscle It predominantly affects adults with obstructive atherosclerotic coronary artery disease, microvascular dysfunction, or coronary vasospasm Clinically, it manifests along a continuum ranging from silent ischemia to exertional angina pectoris, dyspnea, and acute coronary syndromes with isch...
- nih.gov
Myocardial ischemia is a cardiovascular condition defined by a critical imbalance between coronary blood flow and myocardial metabolic demand, leading to inadequate perfusion and oxygenation of the heart muscle Pathophysiologically, cellular hypoxia triggers a shift to anaerobic glycolysis, impaired contractile function, and tissue acidosis, which can progress to cardiomyocyte necrosis if perfusion is not promptly restored
- nih.gov
It predominantly affects adults with obstructive atherosclerotic coronary artery disease, microvascular dysfunction, or coronary vasospasm Clinically, it manifests along a continuum ranging from silent ischemia to exertional angina pectoris, dyspnea, and acute coronary syndromes with ischemic electrocardiographic abnormalities
- nih.gov
Pathophysiologically, cellular hypoxia triggers a shift to anaerobic glycolysis, impaired contractile function, and tissue acidosis, which can progress to cardiomyocyte necrosis if perfusion is not promptly restored
- nih.gov
Pathophysiologically, cellular hypoxia triggers a shift to anaerobic glycolysis, impaired contractile function, and tissue acidosis, which can progress to cardiomyocyte necrosis if perfusion is not promptly restored
- nih.gov
Clinically, it manifests along a continuum ranging from silent ischemia to exertional angina pectoris, dyspnea, and acute coronary syndromes with ischemic electrocardiographic abnormalities
- nih.gov
Clinically, it manifests along a continuum ranging from silent ischemia to exertional angina pectoris, dyspnea, and acute coronary syndromes with ischemic electrocardiographic abnormalities
Personalize your experience
Follow Myocardial ischemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.